| (Values in U.S. Thousands) | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 |
| Sales | 60 | 100 | 3,050 | 0 | 9,000 |
| Sales Growth | -40.00% | -96.72% | unch | -100.00% | unch |
| Net Income | -2,840 | -3,170 | 440 | 10,760 | -6,290 |
| Net Income Growth | +10.41% | -820.45% | -95.91% | +271.07% | +26.00% |
Tracon Pharmaceuticals Inc (TCON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company's product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California.
Fiscal Year End Date: 12/31